Cirdan Ltd’s Post

Pulsed Field Ablation Innovator, Arga, has just raised €54 million in an oversubscribed financing round. The investors included Advent Life Sciences (UK), Earlybird Health (Germany), a new investor Gilde Healthcare (the Netherlands) as well as an undisclosed strategic investor. This start-up was founded by David Naele and Randy Werneth in 2020, to develop Coherent Sine-Burst Electroporation™ (CSE™), a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation. Supporting Argá Medtech SA since its formation, Kellerhals Carrard advised on the Swiss contractual aspects of this round and collaborated with Wilson Sonsini Goodrich & Rosati from the US side. The Kellerhals Carrard team was led by Jean-Luc Chenaux (pictured) (Partner, M&A), and further comprised Frédéric Rochat (Partner, M&A), François Kaiser (Partner, M&A), Serge Migy (Partner, Tax) Virginie A. Rodieux (Partner, IP) as well as Cindy Liu-Ung and Joséphine Marmy (Senior Associates, M&A) and Brian Jurt (Tax advisor). Read the article >> https://lnkd.in/dJe2u5Qu #Legalcommunitych #legaladvisor #financinground

What great news Lucy O'Keeffe for you and all your team CroiValve. We look forward to watching your business grow even more in the coming years and would love to welcome you back again to share your journey with our founders #scaling #globalambition #enterpriseireland #selectstrategies

Long Shortz with Lumos Diagnostics: Who took part in the recent raising? https://buff.ly/3B1ioUu #ASX #ASX200 $LDX Lumos Diagnostics

WISE SpA, a leader in advanced implantable electrodes for neuromonitoring and neuromodulation, has closed a €25 million financing round. 💰 This includes equity investment and a venture debt loan from the European Investment Bank (EIB), supported by InvestEU. The funds will advance the Heron® lead for spinal cord stimulation and commercialize the WISE Cortical Strip (WCS®) for neuromonitoring. Key points: 🧠New investor: Wallaby SpA (Scagliarini family, GVS SpA) joins existing partners. 🧠Transitioned to a Joint Stock Company (S.p.A.). 🧠Focus on Heron® lead development and WCS® commercialization. CEO Luca Ravagnan said: “The contextual EIB decision to enter into a financing agreement with WISE, following thorough due diligence of the company’s business, further demonstrates the growing confidence in our innovative technology to revolutionize the spinal cord stimulation market.” Full article in the comments. #WISE #Neurotech #Neuromodulation #Investment #EIB #neuromonitoring

🔔 Phagenesis Ltd Closes $42 Million Series D Financing 🔔 💰The UK based company has developed a neurostimulation system to treat swallowing dysfunction, has closed its Series D Financing. 👨🔬 Co-founded by Dr. Conor Mulrooney and Professor Shaheen Hamdy and led by CEO Reinhard Krickl the company offers innovative treatments for neurogenic dysphagia using pharyngeal electrical stimulation, PES. 💸 The round was led by EQT Life Sciences and Sectoral Asset Management with participation from new investors British Patient Capital, Northern Gritstone and Aphelion Capital. 📈 The company intends to use the funds to expand operations and development efforts. Recent approval of Phagenyx by the FDA in the US, the investment is primarily intended to support commercialisation in the US and deepen penetration in Europe. #funding #vc #vcfunding #vensight #insights #seriesd  #medtech #investment

Moximed closed a Series D preferred stock financing worth up to $91 million. The funding round includes $61 million and an option to close on up to an additional $30 million. 👏 ⭐ Elevage Medical Technologies, a Patient Square Capital platform, led the round. New investors Cormorant Asset Management, LP and Warren Point Capital joined in the funding. Existing investors New Enterprise Associates (NEA), Future Fund, Advent Life Sciences, Gilde Healthcare, Vertex Ventures HC, GBS Venture Partners and MORGENTHALER VENTURE PARTNERS IX LP all participated. 💬 “This financing is validation of the significant market opportunity for the MISHA Knee System,” said Christopher Gleason, President and CEO of Moximed. 🔗 Learn more: https://lnkd.in/djdDtwkt #MedicalDevice #MedTech #MedicalEquipment #HealthTech #Knee #Orthopaedics #MedicalDevices #Medicine #TechNews #Funding #MedTechFunding #FundingRound #AngelInvestment #GSCapitalConnect

Breaking news! James Hussey, CEO at Seneca Therapeutics, Inc. will join The Keiretsu Family Office Forum as a part of the Family Office Investment Outlook Panel. Register now to hear his thoughts about the current landscape of family office investment: https://lnkd.in/dynZpRff #InvestorCapitalExpo #FamilyOfficeForum #AngelEcosystem #InvestorCapitalExpo2024 #AngelInvesting #AngelCommunity

#Update Spry Therapeutics, a SaaS platform for physical therapy professionals, has raised $15 million in funding. The funds will be used to accelerate SPRY's expansion in the US market. Spry Therapeutics's AI-driven platform automates complex billing tasks, streamlines clinic operations, and boosts efficiency for physical therapists. The company aims to transform physical therapy by addressing key business challenges and improving patient outcomes. Read the story: https://ow.ly/r6k950THJgT Flourish Ventures, Together Fund, Fidelity’s Eight Roads, F-Prime Capital, Ola #SPRYTherapeutics #SaaSPlatform #PhysicalTherapy #FundingNews #HealthTech #AIinHealthcare #ClinicOperations #PatientOutcomes #BusinessChallenges #USMarketExpansion

Our #MarketUpdate report for the week ending February 16th is now available. Highlights include:    🔉US equities ended the week with minor losses due to January’s CPI being higher than expected at 3.1% YoY and 0.3% MoM     🔉Despite the momentum that biotech IPOs have seen so far this year, last week saw no listings; however, 25 companies in the queue suggests that IPO activity will most likely remain elevated in the first half of the year     🔉Gilead Sciences made headlines by expanding their liver portfolio with their $4.3B acquisition of CymaBay Therapeutics, providing Gilead Sciences with CymaBay Therapeutics’s investigational lead candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) with FDA priority review and anticipated U.S. approval in the third quarter of 2024     🔉Freenome, developing blood tests for early cancer detection, raised a $254M venture round led by Roche and joined by a16z Life Sciences Growth Fund, Bain Capital Life Sciences Fund LP, RA Capital Management, and other flagship life sciences investors, making this deal the largest venture financing year-to-date    Read the full report here: https://bit.ly/42JY8k2     #Healthcare #MarketTrends #Biotech #IPO #Cancer #Theraputics #Lifesciences #BBLSA  

🏥 Big strides for SPRY Therapeutics! The SaaS platform for physical therapy professionals has raised $15 million in a new funding round led by Flourish Ventures, Together Fund, and Fidelity's Eight Roads & F-prime Capital, bringing its total funding to $25 million since its 2021 launch. Co-founded by Brijraj Bhuptani (former CTO of Ola) and Riyaz Rehman, SPRY is transforming clinic management by automating complex billing processes and enhancing patient engagement. With this new funding, SPRY is set to expand further into the US market and continue revolutionizing physical therapy management! 🚀💡 #HealthTech #SaaS #Funding #Innovation #SPRY #iAccelerate